- KR₩91bn
- KR₩63bn
- KR₩3bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.8 | ||
| Price to Tang. Book | 1.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.41% | ||
| Return on Equity | -21.36% | ||
| Operating Margin | -394.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 3,363.42 | 3,242.12 | 5,293.45 | 3,125.39 | 3,355.76 | n/a | n/a | -4.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Company’s products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.
Directors
- Won Yil Yoo PRE (52)
- Jong Du Choi OTH (46)
- Jin Wuk Jang OTH (43)
- Song Won Kim OTH (45)
- Myeong Jae Lee OTH (46)
- Wan Je Cho DRC (40)
- Du Sik Kim DRC (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 23rd, 2000
- Public Since
- November 28th, 2013
- No. of Shareholders
- 24,216
- No. of Employees
- 58
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 27,029,784
- Address
- 2F, 13, Yangjipyeon 2-ro, UIWANG, 16009
- Web
- https://www.eyegene.co.kr/
- Phone
- +82 23221687
- Auditors
- Samil Accounting Corp.
Upcoming Events for 185490
Similar to 185490
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 20:33 UTC, shares in EyeGene are trading at KR₩3,350. This share price information is delayed by 15 minutes.
Shares in EyeGene last closed at KR₩3,350 and the price had moved by +8.77% over the past 365 days. In terms of relative price strength the EyeGene share price has outperformed the FTSE Developed Asia Pacific Index by +11.19% over the past year.
There is no consensus recommendation for this security.
Find out moreEyeGene does not currently pay a dividend.
EyeGene does not currently pay a dividend.
EyeGene does not currently pay a dividend.
To buy shares in EyeGene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩3,350, shares in EyeGene had a market capitalisation of KR₩91bn.
Here are the trading details for EyeGene:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 185490
Based on an overall assessment of its quality, value and momentum EyeGene is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in EyeGene is KR₩635. That is 81.04% below the last closing price of KR₩3,350.
Analysts covering EyeGene currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like EyeGene. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +19.76%.
As of the last closing price of KR₩3,350, shares in EyeGene were trading +12.31% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The EyeGene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩3,350.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
EyeGene's management team is headed by:
- Won Yil Yoo - PRE
- Jong Du Choi - OTH
- Jin Wuk Jang - OTH
- Song Won Kim - OTH
- Myeong Jae Lee - OTH
- Wan Je Cho - DRC
- Du Sik Kim - DRC